Page 1

aTyr aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update November 10 , 2021 Positive results reported from Phase 1b / 2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof - of - concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target . Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022 . September follow - on common stock offering generated $ 80 million in net proceeds . Company to host conference call and webcast today , November 10th , at 5:00 p.m. EST / 2 : 00 p.m. PST . SAN DIEGO , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- aTyr Pharma , Inc. ( Nasdaq : LIFE ) , a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways , today announced third quarter 2021 results and provided a corporate update . " The third quarter was a major inflection point for aTyr ; we demonstrated , via clinical proof - of - concept data for ATYR1923 , that our novel tRNA synthetase biology platform has the potential to treat serious diseases , " said Sanjay S. Shukla , M.D. , M.S. , President and Chief Executive Officer of aTyr . " The positive results reported from our Phase 1b / 2a study of ATYR1923 in pulmonary sarcoidosis , our initial interstitial lung disease ( ILD ) indication , suggest that ATYR1923 could be a transformative therapy for patients by reducing steroid burden while improving lung function and measures of sarcoidosis symptoms . We look forward to advancing ATYR1923 to a registrational trial in pulmonary sarcoidosis next year , which will bring us one step closer to delivering a potential new treatment to sarcoidosis patients with clinically meaningful outcomes . " Third Quarter 2021 and Subsequent Period Highlights . Reported positive results from a Phase 1b / 2a multiple - ascending dose , placebo - controlled study of ATYR1923 in 37 patients with pulmonary sarcoidosis . ATYR1923 was safe and well - tolerated at all doses with no drug - related serious adverse events or signal of immunogenicity . Additionally , the study demonstrated consistent dose response for ATYR1923 on key efficacy endpoints and improvements compared to placebo , including measures of steroid reduction , lung function , sarcoidosis symptom measures and inflammatory biomarkers . Based on the results of the study , the company expects to initiate a registrational trial in pulmonary sarcoidosis next year . Furthermore , the data support the expansion of the development of ATYR1923 in other forms of ILD , such as connective tissue disease - related ILD and chronic hypersensitivity pneumonitis . • Announced the presentation of preclinical research demonstrating the effects of ATYR2810 , the company's lead anti - Neuropilin - 2 ( NRP2 ) / VEGF antibody and IND candidate , on tumor associated macrophages at the 2021 Society for Immunotherapy of Cancer Annual Meeting . Treatment of human triple - negative breast cancer cells with ATYR2810 was shown to modulate key immune cells suppressing T - cell mediated anti - tumor responses in the tumor microenvironment and decrease ZEB1 gene expression , a master transcription factor regulating epithelial - mesenchymal transition , a process that is of great importance in regulating tumor growth , progression and metastatic cascade . These data advance the understanding of ATYR2810's mechanism of action and the process by which it may inhibit tumor progression and disrupt immune invasion and will support clinical development for ATYR2810 , including a planned Phase 1 study in cancer next year . • Appointed Robert W. Ashworth , PhD , as Vice President of Regulatory Affairs . Dr. Ashworth is an industry veteran with more than 35 years of regulatory and drug development experience , including a track record of contributing to the FDA approval of more than 12 new drugs . Dr. Ashworth will serve as a member of the company's executive leadership team , overseeing regulatory affairs functions and strategies . • Raised net proceeds of $ 80.6 million through the issuance of 10,781,250 shares of common stock in September 2021 from a public offering . Third Quarter 2021 Financial Highlights • Cash & Investment Position : Cash , cash equivalents and investments as of September 30 , 2021 were $ 116.4 million . • R & D Expenses : Research and development expenses were $ 5.1 million for the third quarter of 2021 , which consisted primarily of product development costs for ATYR1923 and ATYR2810 programs . • G & A Expenses : General and administrative expenses were $ 2.6 million for the third quarter of 2021 . • Shares Outstanding : Commons shares outstanding were 27,790,677 as of September 30 , 2021 .